A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 10007-10007 ◽  
Author(s):  
S. George ◽  
M. von Mehren ◽  
M. C. Heinrich ◽  
Q. Wang ◽  
C. L. Corless ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Stromal Tumor ◽  
Multicenter Phase

scholarly journals Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study

2019 ◽  
Vol 30 ◽  
pp. vi88
Author(s):  
Yoichi Naito ◽  
Toshihiko Doi ◽  
Tsuyoshi Takahashi ◽  
Toshihiro Kudo ◽  
Narikazu Boku ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Stromal Tumor ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Imatinib Resistant

A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 10006-10006 ◽  
Author(s):  
J. C. Trent ◽  
K. Wathen ◽  
M. von Mehren ◽  
B. L. Samuels ◽  
A. P. Staddon ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Stromal Tumor ◽  
Imatinib Resistant
Sign in / Sign up

Export Citation Format

Share Document